Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2560)	7/24/2006 3:16:20 PM
From: Ian@SI	Respond to of 7424

PRAN up 60% on re-release of last week's PR on PBT2 - pre clinical Alzheimer's research. Was up about 80% earlier today.

To: tuck who wrote (2560)	7/25/2006 9:51:16 AM
From: Saulamanca	Read Replies (1) \| Respond to of 7424

MNTA up another 30% MNTA Momenta Pharma and Sandoz sign exclusive collaboration to develop complex generics and follow-on versions of biotechnology drugs Co announces an exclusive collaboration with Sandoz, the generics business of Novartis (NVS), to develop four follow-on and complex generic versions of previously approved recombinant biotechnology and complex drugs. As part of the collaboration, Sandoz will make an initial payment of $75 mln to the co for the purchase of approx 4.7 mln shares at a price of $15.93 per share, a 30% premium to the trailing 30-day average. The co is also eligible to receive up to $188 mln in additional payments if all milestones are achieved for the four product candidates. The collaboration will include one late-stage compound from the co's pipeline and two late-stage compounds from Sandoz.